Graham Collins: Starglo – A practice changing study

Graham Collins, Associate Professor of Hematology at the Oxford Cancer and Hematology Center shared a post on X:

“Starglo – EHA2024 plenary:

•  R-GemOx vs. Glofit-GemOx R/R DLBCL
• 2L (SCT-ineligible) / 3L+
•  OS primary EP
•  Med OS 12.9 months (con) vS 25.5 months
•  More TEAEs but more Rx exposure
• More deaths but mainly COVID
• G1/2 CRS as expected

A practice-changing study. ”

Source: Graham Collins/X